Level C· Early human research exploring benefitsProspective StudyPubMed

Editorial Commentary: Precise Nomenclature Is Critical for Evaluating Progress in the Field of Lipoaspirate-Derived Stem Cell Therapy.

Fortier LA.

Prospective Study on Osteoarthritis, Ankle Injury, published in Arthroscopy (2016) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Arthroscopy (2016)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
27151452
DOI
10.1016/j.arthro.2016.03.001
Citations
2

Abstract (original English)

In a Level III study, the addition of adipose-based cell therapy significantly improved the clinical outcome and arthroscopic appearance of articular cartilage in patients with osteoarthritic varus ankles that were treated with the combinational operative techniques of lateral sliding calcaneal osteotomy and microfracture. Use of adipose-based therapies from lipoaspirate is increasing, with many different types of processing available, resulting in very different biological products. The mesenchymal stem cell therapy terminology used in the article could be more precise, and the contribution of adipose cells to the outcome is confounded by the surgical procedures performed. On the positive side, the article is a good start to encourage the orthopaedic community to provide the evidence both in clinical outcome and in determining what is in the mixture of cells administered to the patient, so that the efficacy of adipose-based cell therapy can be transparent and critically evaluated.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Cartilage, ArticularCell- and Tissue-Based TherapyHumansMesenchymal Stem CellsOsteotomyStem Cell Transplantation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research